Tedizolid Phosphate(CAS NO.:856867-55-5)
Basic information
Product Name: Tedizolid Phosphate
Synonyms:
CAS: 856867-55-5
MF: C17H16FN6O6P
MW: 450.32
Chemical Properties
Boiling Point: 725.6±70.0 °C(Predicted)
Density: 1.75±0.1 g/cm3(Predicted)
storage temp: under inert gas (nitrogen or Argon) at 2-8°C
Solubility: DMSO (Slightly, Sonicated)
Form: Solid
Pka: 1.81±0.10(Predicted)
Color: White to Off-White
InChI: NA
InChIKey: NA
SMILES: NA
product description
There were fewer adverse effects in gastrointestinal and blood plateletless than linezolid and a lower incidence of drug resistance. Trials have also shown that tedizolid is also better tolerated than vancomycin. FDA-approved dosage forms are available as injections and tablets to facilitate clinical switching, and the dosage is once a day for six days, which is more convenient for clinical use than linezolid twice a day for ten days. Therefore, in view of its good clinical effect, smaller dose and shorter dosing cycle, it is suitable for a wide range of people and has a broad market capacity.
Antimicrobial therapy: Tedizolid phosphate is an antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) in adults caused by specific bacteria.
Gram-positive infections: it is susceptible to gram-positive bacteria, including methicillin-resistant Staphylococcus aureus and has activity against gram-positive bacteria.
Inhibition of protein synthesis: Tedizolid phosphate effectively inhibits the synthesis of bacterial proteins and exerts antibacterial effects by tightly binding with the 50S subunit of bacterial ribosomes.
Clinical trials: In phase III clinical trials, tedizolid phosphate has been shown to be as clinically effective as linezolid, but has fewer adverse effects than linezolid in gastrointestinal tract and thrombocytopenia, and has a lower incidence of drug resistance.
Route of administration: Tedizolid phosphate can be administered in equal doses by oral or intravenous routes, which has good skin and soft tissue penetration and is convenient for the treatment of outpatient patients.
Market outlook: The drug is expected to exceed $1 billion in drug sales by 2020, and through an agreement between Cubist Pharmaceuticals and Bayer, Tedizolid's sales performance will be enhanced in regions not currently covered by Cubist, including Asia, Latin America and parts of the Middle East